Blood stem cell mobilization and collection in patients with chronic lymphocytic leukaemia: a nationwide analysis. (scientific article published on 29 October 2007)

The VAD chemotherapy regimen plus a G-CSF dose of 10 μg/kg is as effective and less toxic than high-dose cyclophosphamide plus a G-CSF dose of 5 μg/kg for progenitor cell mobilization: results from a monocentric study of 82 patients

Q57218350

Autologous hematopoietic stem cell transplantation as salvage treatment for advanced B cell chronic lymphocytic leukemia

Q58041789

Results of the MRC pilot study show autografting for younger patients with chronic lymphocytic leukemia is safe and achieves a high percentage of molecular responses

Q61868167

Autologous blood cell transplantation in B-CLL: response to chemotherapy prior to mobilization predicts the stem cell yield

Q73348795

Fludarabine containing-regimens may adversely affect peripheral blood stem cell collection in low-grade non Hodgkin lymphoma patients

Q73559158

Peripheral blood stem cell (PBSC) mobilization and transplantation after fludarabine therapy in chronic lymphocytic leukaemia (CLL): a report of the European Blood and Marrow Transplantation (EBMT) CLL subcommittee on behalf of the EBMT Chronic Leuk

Q73664063

Factors associated with successful mobilization of peripheral blood progenitor cells in 200 patients with lymphoid malignancies

Q77476840

High-dose melphalan (200 mg/m2) supported by autologous stem cell transplantation is safe and effective in elderly (>or=65 years) myeloma patients: comparison with younger patients treated on the same protocol

Q83277288

Autologous stem cell transplantation in patients with chronic lymphocytic leukaemia: the Finnish experience

Q83339318

Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia

Q28140129

Genomic aberrations and survival in chronic lymphocytic leukemia

Q28141442

Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study

Q33342242

Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia

Q33368885

Impact of frontline fludarabine and cyclophosphamide combined treatment on peripheral blood stem cell mobilization in B-cell chronic lymphocytic leukemia

Q34229807

The use of AMD3100 plus G-CSF for autologous hematopoietic progenitor cell mobilization is superior to G-CSF alone

Q34418466

Autologous and allogeneic stem cell transplantations for poor-risk chronic lymphocytic leukemia

Q35848136

Indications for allogeneic stem cell transplantation in chronic lymphocytic leukemia: the EBMT transplant consensus.

Q36654926

PBSC mobilization, collection and positive selection in patients with chronic lymphocytic leukemia

Q40828128

Cyclophosphamide, etoposide and G-CSF to mobilize peripheral blood stem cells for autologous stem cell transplantation in patients with lymphoma

Q44123961

Successful CD34+ cell mobilization by intermediate-dose Ara-C in chronic lymphocytic leukemia patients treated with sequential fludarabine and Campath-1H.

Q44637372

Favorable treatment outcome in non-Hodgkin's lymphoma patients with "poor" mobilization of peripheral blood progenitor cells.

Q45984928

Mobilization of peripheral blood stem cells in CLL patients after front-line fludarabine treatment.

Q46382026

Fludarabine in combination with alemtuzumab is effective and feasible in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: results of a phase II trial

Q46689599

The prognostic impact of autologous stem cell transplantation in patients with chronic lymphocytic leukemia: a risk-matched analysis based on the VH gene mutational status

Q47325357

Prediction of mobilisation failure in patients with non-Hodgkin's lymphoma

Q47913355

Progenitor-cell mobilization after low-dose cyclophosphamide and granulocyte colony-stimulating factor: an analysis of progenitor-cell quantity and quality and factors predicting for these parameters in 101 pretreated patients with malignant lymphom

Q50970785

P433

issue

P407

language of work or name

English

Q1860

P921

main subject

lymphocyte

Q715347

leukemia

Q29496

P304

page(s)

239-244

P577

publication date

2007-10-29

P1433

published in

Bone Marrow Transplantation

Q4941523

P1476

title

Blood stem cell mobilization and collection in patients with chronic lymphocytic leukaemia: a nationwide analysis

P478

volume

Reverse relations

cites work (P2860)

Q84496850	Autologous transplantation in CLL patients with B and C Binet stages: final results of the prospective randomized GOELAMS LLC 98 trial
Q46416781	Bendamustine, but not fludarabine, exhibits a low stem cell toxicity in vitro
Q43135383	Efficacy of rituximab and cladribine in patients with chronic lymphocytic leukemia and feasibility of stem cell mobilization: a prospective multicenter phase II trial (protocol SAKK 34/02).
Q35563121	Ex vivo expansion of human mobilized peripheral blood stem cells using epigenetic modifiers
Q37782403	Mobilization strategies in hard‐to‐mobilize patients with lymphoid malignancies
Q42592824	Proposed definition of 'poor mobilizer' in lymphoma and multiple myeloma: an analytic hierarchy process by ad hoc working group Gruppo ItalianoTrapianto di Midollo Osseo
Q27692619	Regulatory systems in bone marrow for hematopoietic stem/progenitor cells mobilization and homing.
Q46775470	Risk factors for a poor hematopoietic stem cell mobilization
Q38688055	Stem cell transplantation in multiple myeloma and other plasma cell disorders (report from an EBMT preceptorship meeting).